Refine by
Brain Blood Articles & Analysis
49 news found
Ace Therapeutics, a biotechnology company pioneering novel central nervous system (CNS) delivery solutions, today announced the release of its BBBporter™ technology platform. This innovative platform is specifically designed to overcome the primary challenge in treating brain diseases: the blood-brain barrier (BBB). By leveraging a suite of biomimetic and AI-powered technologies, ...
Nubeqa now approved for metastatic hormone-sensitive prostate cancer as well as non-metastatic castration-resistant prostate cancer Additional indication based on data from the pivotal Phase III ARASENS trial The Chinese National Medical Products Administration (NMPA) has approved the oral androgen receptor inhibitor (ARi) Nubeqa™ (darolutamide) in combination with docetaxel for the ...
ByBayer AG
Darolutamide approved for metastatic prostate cancer as well as non-metastatic castration-resistant prostate cancer New approval based on data from the pivotal Phase III ARASENS trial The Ministry of Health, Labor and Welfare (MHLW) in Japan has approved the oral androgen receptor inhibitor (ARi) darolutamide plus ADT in combination with docetaxel in the indication of metastatic prostate ...
ByBayer AG
Endogenous peptides with analgesic potential include endorphins via the mu receptor, dynorphins via the kappa receptor and enkephalins via the delta receptor. Kappa and delta opioid agonists have been shown to provide analgesic benefit while sparing toxic mu agonist toxicity1 . Preclinical data supports analgesia from enkephalin without significant opioid tolerance, or drug liking. Unfortunately, ...
There is pharmacological evidence of activity of MET enabled enkephalin in morphine-tolerant animals. We believe the preliminary data from these early animal studies of NES100 support our belief that Envelta™ may have comparable preclinical activity to morphine in all animal pain models tested without the drug seeking, respiratory depression, and tolerance associated with opioids. ...
Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, and Kurve Therapeutics, a next-generation medtech and drug formulation company, today announced positive preclinical study results for intranasal administration of a cell-based oncolytic virus bearing product. The results ...
Orion Biotechnology Canada Ltd., a clinical stage company unlocking the therapeutic potential of G Protein-Coupled Receptors (GPCRs) with a novel drug modality, proven discovery platform and best-in-class molecules, today announced that it is receiving advisory services and conditional funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). The ...
BOSTON, November 3, 2022 – Elucid, Inc., a leading medical technology company providing physicians with AI-powered imaging analysis software to characterize cardiovascular disease, today announced the addition of Michael D. Lesh, MD, FACC, to its Board of Directors. “We look forward to what Dr. Lesh will bring to the board with his extensive background as a cardiologist, medtech ...
ByElucid
Next-generation Medtech innovator Kurve Therapeutics begins an equity crowdfunding journey with its $50 million Regulation A+ raise. Private investors can now invest in a company aiming to disrupt and transform a $1.3 trillion dementia market alone while benefiting millions living with neurodegenerative diseases. Diseases like Dementia and Alzheimer’s afflict millions of people across the ...
New results from the Phase III ARASENS trial evaluating quality of life (QoL) and patient-relevant endpoints for darolutamide plus androgen deprivation therapy (ADT) and docetaxel in patients with metastatic hormone-sensitive prostate cancer (mHSPC) show that, in addition to extending overall survival (OS), darolutamide has a strong tolerability profile and ability to maintain patient QoL with ...
ByBayer AG
Canaquest Medical Corp (OTC Pink:CANQF) (the "Company" or "CanaQuest"), an award-winning, Clinical Stage/Life-Sciences company focused on drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and specific brain receptors, today announced its US launch of all-natural Mentanine® (cannabidiol "CBD" + IP, Omega-3s, DHA, EPA formula) in ...
Canaquest Medical Corp (OTC PINK:CANQF) (the “Company” or “CanaQuest“), an award-winning, Clinical Stage/Life-Sciences company focused on drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and specific brain receptors, today announced its US launch of all-natural Mentanine (cannabidiol “CBD” + IP, Omega-3s, ...
Kurve Therapeutics, a next-generation medtech innovator focused on developing treatments for neurodegenerative diseases, announced it has filed a Form 1-A preliminary offering circular with the U.S. Securities and Exchange Commission (SEC) for a $50 million funding round [kurvetx.com/offering-circular]. Investment opportunities are now open to public investors for offers starting at $580 for 100 ...
Darolutamide now has indications in both non-metastatic castration-resistant prostate cancer (nmCRPC) for men at high risk of developing metastatic disease and metastatic hormone-sensitive prostate cancer (mHSPC) Today’s approval under the FDA’s Real-Time Oncology Review (RTOR) pilot program was based on the pivotal Phase III ARASENS trial, which showed a significant overall ...
ByBayer AG
Rapid Medical, a leading developer of advanced neurovascular devices, announces FDA 510(k) clearance for TIGERTRIEVER 13 for large vessel occlusions at the 2022 Society of NeuroInterventional Surgery’s (SNIS) 19th Annual Meeting in Toronto. TIGERTRIEVER 13 is the smallest revascularization device in the world to date and is designed to remove thrombus from delicate brain blood vessels ...
Kurve Therapeutics has succeeded in bypassing the blood-brain barrier with their patented Controlled Particle Dispersion® (CPD) technology, creating new hope in the treatment of central nervous system disorders. The company urges CNS researchers to reach out for collaboration in providing care for this very large global population. Led by a team of experienced entrepreneurs with ...
VeriSIM Life (VeriSIM), the leading artificial intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development, today announced that it has entered into a partnership agreement with Total Brain, an applied, integrative neuroscience company, to create breakthrough neurodata-driven actionable insights for developing novel drugs to treat a wide range of neurological ...
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced preclinical data demonstrating the efficacy and safety of AVR-RD-03 gene therapy in a mouse model of infantile onset Pompe disease. The results, which will be presented today during the “Disease models and Clinical Applications: ...
Bayer today announced the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for the oral androgen receptor inhibitor (ARi) darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). The application is being conducted under the FDA Oncology Center of ...
ByBayer AG
Inscopix, Inc., a neuroscience company helping decode the brain for tomorrow’s treatments, announced that it has launched a new application for its miniscope-based platforms to investigate neuronal activity and blood flow simultaneously, a novel research method that may prove critical to studying neurovascular dynamics in the context of aging, dementia, stroke and other debilitating ...